Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Heartburn

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with Non-Erosive Gastroesophageal Reflux Disease identifying their main symptom as heartburn.~  * History of episodes of heartburn for 6 months or longer prior to screening.~ * History of episodes of heartburn for 4 or more days during the 7 days prior to Day -1 as recorded in the electronic diary.~Exclusion Criteria:~* Use of prescription or non-prescription proton pump inhibitors (PPIs), histamine (H2) receptor antagonists, sucralfate, misoprostol or prokinetics throughout the study~* Erosive Esophagitis seen on endoscopy during study screening.~* Co-existing diseases affecting the esophagus.~* Abnormal laboratory values that suggest significant clinical disease.~* Known acquired immunodeficiency syndrome (AIDS)~* Females pregnant or lactating.~* History of Alcohol abuse.~* History of Cancer within 3 years prior to screening.~* Chronic (\>12 doses per month) use of nonsteroidal anti-inflammatory drugs (NSAIDs) or cyclo-oxygenase-2 (COX-2) inhibitors~* Use of antacids (except for study supplied Gelusil® )~* Use of drugs with significant anticholinergic effects~* Need for continuous anticoagulant (blood thinner) therapy~* Endoscopic Barrett's esophagus and/or definite dysplastic changes in the esophagus~* History of dilatation of esophageal strictures, other than a Schatzki's ring (a ring of mucosal tissue near the lower esophageal sphincter)~* Current or historical evidence of Zollinger-Ellison syndrome or other hypersecretory condition~* History of gastric, duodenal or esophageal surgery except simple oversew of an ulcer~* Subjects who, in the opinion of the investigator, are unable to comply with the requirements of the study or are unsuitable for any reason.~* Acute upper gastrointestinal (UGI) hemorrhage within 4 weeks of the Screening endoscopy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dexlansoprazole MR 60 mg QD (Type: EXPERIMENTAL): None
- Dexlansoprazole MR 90 mg QD (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).